Sermorelin Monitoring Schedule, Labs & Exams

How Sermorelin Works: The Mechanism Behind the Monitoring

Sermorelin is a synthetic 29-amino-acid analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors, stimulates pulsatile GH secretion, and raises downstream IGF-1. Because it works through the pituitary rather than delivering exogenous GH directly, monitoring focuses on whether the pituitary axis responds, not just whether a drug level is present.

Pituitary-Level Action

The native GHRH peptide spans 44 amino acids. Sermorelin retains the first 29, which carry the full receptor-binding and signal-transduction activity. After subcutaneous injection, peak GH secretion typically occurs within 15 to 30 minutes, mirroring the physiological nocturnal GH pulse. Administering the dose at bedtime takes advantage of the natural sleep-associated GH surge, a concept supported by work on GH secretory patterns in adults. (Veldhuis et al., JCEM 1987)

The IGF-1 Bridge

The liver converts pulsatile GH secretion into sustained IGF-1 production. IGF-1 has a half-life of roughly 15 hours, making it a far more stable biomarker than GH itself (GH half-life: 20 to 30 minutes). This is why every monitoring protocol anchors on IGF-1 rather than serum GH. (Clemmons, NEJM 2007)

Why the Axis Preserves Safety

Unlike recombinant human GH (rhGH), sermorelin preserves the normal negative-feedback loop: rising IGF-1 feeds back on the hypothalamus and pituitary to suppress further GHRH and GH release. This self-limiting physiology is one reason some clinicians prefer GHRH analogues in adults with relative GH deficiency, and it shapes the monitoring schedule, runaway IGF-1 elevation is less likely but still requires periodic confirmation. (Corpas et al., Endocrine Reviews 1993)

Baseline Evaluation Before the First Injection

No dose should be given until a complete baseline panel is documented. This protects the patient and gives the prescribing clinician a valid reference point for every future result.

Required Laboratory Tests

Order all of the following before dose day one:

• IGF-1 (age- and sex-referenced): establishes whether true deficiency exists and sets the pre-treatment floor.
• Fasting glucose and HbA1c: GH promotes lipolysis and mild insulin resistance; a pre-existing dysglycemia must be documented. The American Diabetes Association classifies HbA1c 5.7 to 6.4% as prediabetes and warrants heightened glucose surveillance during therapy. (ADA Standards of Care 2024)
• Comprehensive metabolic panel (CMP): renal and hepatic function affect IGF-1 synthesis; baseline creatinine and ALT are reference points for safety labs at later visits.
• CBC: not directly altered by sermorelin, but establishes hematologic baseline.
• Thyroid panel (TSH, free T4): untreated hypothyroidism blunts the pituitary GH response. The Endocrine Society guideline on GH deficiency in adults explicitly states that thyroid status must be optimized before GH-axis therapy begins. (Molitch et al., JCEM 2011)
• Fasting lipid panel: GH deficiency is associated with dyslipidemia; lipids often improve with successful treatment, giving a secondary efficacy signal.
• Cortisol (AM, 8 a.m.): hypopituitarism can present as isolated GH deficiency or as panhypopituitarism; unrecognized adrenal insufficiency is dangerous.
• Prolactin: screens for pituitary pathology before attributing symptoms solely to GH axis dysfunction.

Physical Examination Findings to Document

Record body weight, waist circumference, blood pressure, and heart rate. Body composition changes (lean mass gain, visceral fat reduction) are the patient-reported endpoints most commonly associated with GHRH therapy in adults, and having a numerical baseline allows objective confirmation at follow-up. (Svensson et al., JCEM 2000)

Imaging Considerations

Pituitary MRI is not mandatory for every adult starting sermorelin at a 503A compounding pharmacy. It is required when clinical features suggest a structural lesion: bitemporal visual field defects, headache with optic changes, or multiple pituitary hormone deficiencies on baseline labs. If MRI identifies a pituitary adenoma, sermorelin is contraindicated until a neuroendocrinologist clears the patient.

The 4 to 6 Week Check: First Signal of Response

The 4 to 6 week visit is a safety and early-efficacy screen, not a definitive dose-titration visit. IGF-1 takes 3 to 4 weeks to stabilize after any dose change.

What to Measure

Order IGF-1 and fasting glucose at minimum. Many protocols add a repeat CMP to confirm no renal or hepatic signal. Do not add lipids yet, lipid changes require at least 3 months of stable IGF-1 to manifest.

How to Interpret Early IGF-1 Results

If IGF-1 remains below the lower quartile of the age-adjusted range after 4 to 6 weeks at 200 to 300 mcg nightly, a dose increase to 300 to 500 mcg may be appropriate, subject to clinical judgement and patient tolerance. If IGF-1 has already reached the upper quartile of the range, maintain the current dose and confirm at the 3-month visit rather than reducing prematurely. (Giustina et al., JCEM 2008)

Glucose Signal at This Stage

A fasting glucose rise of more than 10 mg/dL from baseline at 4 to 6 weeks is an early warning requiring dietary review and, in patients near prediabetes thresholds, possible dose reduction. GH-mediated insulin resistance is dose-dependent and time-limited in most patients, but the signal must not be dismissed. (Moller and Jorgensen, JCEM 2009)

The 3-Month Visit: Primary Dose-Titration Checkpoint

Three months of consistent nightly dosing allows IGF-1 to reach a true pharmacodynamic steady state. This is the first visit where dose titration decisions carry full confidence.

Full Lab Panel at 3 Months

| Test | Rationale | |---|---| | IGF-1 | Primary efficacy endpoint; target mid-to-upper age-adjusted range | | Fasting glucose | GH-related insulin resistance; compare to baseline | | HbA1c | Cumulative glycemic signal over preceding 10 to 12 weeks | | CMP | Renal and hepatic safety | | Lipid panel | First lipid check post-baseline; LDL and triglycerides may shift | | TSH | Re-screen if thyroid symptoms emerge |

Dose Adjustment Algorithm

If IGF-1 sits below the mid-range at 3 months with no safety signals, increase the dose by 100 mcg and recheck at 6 months. If IGF-1 exceeds the upper limit of the age-adjusted reference range, reduce the dose by 100 mcg and recheck at 6 months. If IGF-1 is in the middle 50% of the reference range with no adverse signals, continue unchanged.

The Endocrine Society growth hormone deficiency guideline uses a similar IGF-1-anchored titration logic for rhGH, which maps conceptually to sermorelin given the shared downstream biomarker. (Molitch et al., JCEM 2011)

Patient-Reported Outcome Metrics at 3 Months

Ask explicitly about:

• Sleep quality (sermorelin's nocturnal dosing often improves slow-wave sleep within 4 to 8 weeks)
• Recovery time from exercise
• Body composition perception (subjective before objective changes appear on DEXA)
• Injection-site reactions (transient redness and swelling occur in roughly 17% of patients per prescribing data from compounded GHRH products)

The 6-Month and Ongoing Monitoring Schedule

After the 3-month titration, monitoring shifts to a 6-month rhythm for stable patients.

Every 6 Months: Core Panel

• IGF-1
• Fasting glucose
• HbA1c
• CMP
• Lipid panel

Annual additions: CBC, TSH, free T4, AM cortisol if any clinical concern, and body composition assessment (DEXA or validated anthropometrics).

IGF-1 Targets by Age Group

IGF-1 reference ranges are strongly age-dependent. Using an un-adjusted upper limit of normal is a common error that leads to under-dosing older patients and over-dosing younger ones. The following are approximate mid-range values from the Endocrine Society normative data:

• Age 20 to 29: 200 to 350 ng/mL
• Age 30 to 39: 175 to 300 ng/mL
• Age 40 to 49: 155 to 275 ng/mL
• Age 50 to 59: 135 to 250 ng/mL
• Age 60 to 69: 110 to 220 ng/mL

These figures vary by assay platform. Always interpret IGF-1 against the laboratory's own age- and sex-specific reference range, and note which immunoassay platform was used, Immulite and Luminex platforms can differ by 15 to 20% for the same sample. (Clemmons, JCEM 2012)

Lipid Trajectory as a Secondary Efficacy Signal

Successful GH-axis stimulation typically lowers LDL cholesterol by 5 to 10% and total cholesterol by 4 to 7% over 6 to 12 months in GH-deficient adults. The KIMS observational database (N=2,589 GH-deficient adults on rhGH replacement) showed a mean LDL reduction of 8.4% at 12 months. (Abs et al., JCEM 1997) Sermorelin produces smaller and less consistent lipid shifts than rhGH because IGF-1 increments are more modest, but a trend toward lower LDL by month 6 is a positive signal that the axis is responding.

Glucose and HbA1c Surveillance Long-Term

GH is a counter-regulatory hormone. Sustained elevation of IGF-1 above the upper limit of the age-adjusted reference range is associated with worsening insulin sensitivity. In the GH Deficiency in Adults consensus statement, the Endocrine Society notes that "patients with glucose intolerance or diabetes require more frequent glucose monitoring during GH-axis therapy." (Molitch et al., JCEM 2011) Apply this guidance to sermorelin: patients with HbA1c above 5.7% at baseline should have fasting glucose and HbA1c checked every 3 months, not every 6.

Pediatric Evidence: What Walker et al. 1990 Showed

The foundational clinical trial for sermorelin in growth-hormone-deficient children is Walker et al. (Pediatrics 1990), which remains the most-cited efficacy study for this compound. The trial enrolled children with documented GHD and showed that sermorelin produced a statistically significant increase in growth velocity compared to placebo over 6 months. (Walker et al., Pediatrics 1990)

Pediatric Monitoring Differs Substantially

In children, the primary monitoring endpoints are growth velocity (cm/year), bone age X-ray, and IGF-1 rather than metabolic markers. Height velocity is measured every 3 to 6 months. Bone age films (left hand and wrist radiograph) are obtained annually to assess skeletal maturation relative to chronological age. Premature epiphyseal closure from excessive IGF-1 stimulation is the primary pediatric safety concern.

Why Adult Evidence Remains Limited

Adult sermorelin trials are sparse. Most adult evidence for GHRH-analogue therapy extrapolates from studies of tesamorelin (a stabilized GHRH analogue approved by the FDA for HIV-associated lipodystrophy) and from the broader rhGH literature. The EGRIFTA SV prescribing information provides relevant safety benchmarks for GHRH-class compounds in adults. (FDA EGRIFTA SV Label) Adult sermorelin prescribing in a 503A context is therefore off-label and should be framed as such in patient consent documentation.

Safety Signals That Require Immediate Action

IGF-1 Above the Upper Limit of Normal

An IGF-1 exceeding the laboratory's upper limit of the age-adjusted reference range on two consecutive measurements requires dose reduction or temporary discontinuation. Supraphysiologic IGF-1 is associated with increased risk of certain cancers, a concern documented in the epidemiological literature on acromegaly and IGF-1 levels. (Renehan et al., Lancet 2004)

New or Worsening Edema

Fluid retention is a class effect of GH-axis stimulation. Mild ankle edema affects approximately 10 to 15% of adult patients starting GHRH therapy. Severe or rapid-onset edema, particularly with dyspnea, requires cardiac evaluation before therapy continues. (Abs et al., JCEM 1997)

Carpal Tunnel Symptoms

Paresthesias in the median nerve distribution appearing within the first 2 to 3 months of therapy are a recognized adverse effect of GH-axis stimulation. Dose reduction resolves symptoms in most cases without requiring permanent discontinuation.

Any New Malignancy Diagnosis

Active malignancy is an absolute contraindication to sermorelin therapy. If a patient on therapy receives a new cancer diagnosis, sermorelin should be stopped immediately. GH and IGF-1 both have mitogenic properties, and no safety data support continuation during active oncologic treatment.

Practical Considerations for the Ordering Clinician

Assay Consistency

Always use the same laboratory for serial IGF-1 measurements. Switching platforms mid-treatment introduces assay variance that can mimic a real clinical change. Document the assay method (typically chemiluminescent immunoassay) at baseline and confirm each follow-up sample uses the same method.

Timing of Blood Draw

IGF-1 is relatively stable throughout the day and does not require fasting. Fasting glucose obviously does. Scheduling a single early-morning fasted blood draw captures both markers efficiently. No specific interval between injection and blood draw is required for IGF-1, as its half-life buffers the pulsatile GH release.

Injection Technique and Site Rotation

Subcutaneous sermorelin is typically injected into the abdomen or lateral thigh. Consistent site rotation prevents lipohypertrophy. A brief exam of injection sites at each visit takes less than 60 seconds and catches localized reactions before they become a reason for non-adherence.

The HealthRX Sermorelin Monitoring Timeline (Condensed Reference)

| Timepoint | Minimum Labs | Optional Additions | |---|---|---| | Baseline | IGF-1, FG, HbA1c, CMP, CBC, TSH, FT4, lipids, AM cortisol, prolactin | Pituitary MRI if indicated | | 4 to 6 weeks | IGF-1, fasting glucose | CMP | | 3 months | IGF-1, FG, HbA1c, CMP, lipids, TSH | DEXA body composition | | 6 months | IGF-1, FG, HbA1c, CMP, lipids | CBC, AM cortisol if new symptoms | | 12 months | Full baseline panel | DEXA, bone age (pediatrics) | | Every 6 months thereafter | IGF-1, FG, HbA1c, CMP, lipids | Per clinical judgement |

When to Discontinue Sermorelin

Discontinuation is appropriate when:

1. IGF-1 fails to rise above the lower quartile of the reference range after 6 months at maximum tolerated dose (therapeutic failure).
2. New malignancy is diagnosed.
3. Pregnancy is confirmed (no safety data in pregnancy).
4. Persistent fasting glucose above 126 mg/dL or HbA1c above 6.5% despite dose reduction.
5. Intolerable injection-site reactions or systemic hypersensitivity.

A slow taper is not required because sermorelin has no direct hormonal depot and GH secretion returns to pre-treatment baseline within days of stopping. (Corpas et al., Endocrine Reviews 1993)